Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia

Abstract

Aim: This study aimed to evaluate the real-world efficacy and safety of lorlatinib in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior ALK tyrosine kinase inhibitor (TKI).

Methods: The dataset included 82 subjects with metastatic NSCLC, who received lorlatinib upon compassionate use program or routine treatment between January 2017 and May 2025. All patients involved in this study responded to a prior ALK inhibitor for at least 4 months and switched to the above drug due to disease progression.

Results: The overall objective response rate (ORR) was 64.6%, with the disease control rate (DCR) of 96.3%. Among 65 patients with brain metastases, the intracranial ORR and DCR were 66.2% and 96.9%, respectively. After a median follow-up of 82.7 months, the median progression-free survival (PFS) was 66.7 months (95% CI, 40.5–75.0 months), while the median overall survival (OS) was not reached (NR) (95% CI, NR–NR). Patients who had benefited from prior ALK TKI for more than 12 months achieved significantly longer PFS (NR vs. 34.0 months;p = 0.013) and OS (NR vs. 39.4 months; p = 0.002). Multivariate analysis showed that prior response to ALK TKI of less than 12 months was an independent negative predictor of survival (PFS: p = 0.039, OS: p = 0.027). Treatment-related adverse events (AEs) were reported in 75.6% of patients, with 8.1% experiencing grade 3 or higher toxicity; no treatment-related AEs led to permanent discontinuation of lorlatinib.

Conclusions: This real-world dataset demonstrates an unusually pronounced benefit from lorlatinib in selected patients who progressed on early-generation TKIs, especially in long-term responders to prior therapy. However, the observed outcomes should be interpreted within the context of patient selection. The enrichment for prior responders limits the generalizability to unselected post-TKI populations, including those with primary resistance.

Keywords

real-world evidence / lorlatinib / ALK / tyrosine kinase inhibitor / NSCLC / efficacy / safety

References

[1] Cognigni V, Pecci F, Lupi A, Pinterpe G, De Filippis C, Felicetti C, et al. The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. Cancers (Basel). 2022; 14: 4765.

[2] Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al.; ESMO Guidelines Committee. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34: 339-57.

[3] Yadav V, Reang J, Vinita, Sharma PC, Sharma K, Kumar D, et al. Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment. Eur J Med Chem Rep. 2024; 10: 100142.

[4] Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012; 4: 120ra17.

[5] Parvaresh H, Roozitalab G, Golandam F, Behzadi P, Jabbarzadeh Kaboli P. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions. Biomedicines. 2024; 12: 297.

[6] Zhao M, Shao T, Shao H, Zhou C, Tang W. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2024; 24: 186.

[7] Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018; 19: 1654-67.

[8] Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 2024; 42: 3400-9.

[9] Nagasaka M, Ou SI. Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. J Thorac Oncol. 2021; 16: 532-6.

[10] Pérol M, Swalduz A. Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate? J Clin Oncol. 2022; 40: 3564-8.

[11] Ou SI, Solomon BJ, Besse B, Bearz A, Lin CC, Chiari R, et al. Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report. J Thorac Oncol. 2025; 20: 513-20.

[12] Calles A, Alonso M, Martín-Martorell P, Gómez A, de Castro J, Martínez-Aguillo M, et al.; Spanish Lung Cancer Group. Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain. Cancer Treat Res Commun. 2025; 43: 100905.

[13] Tian G, Nie J, Dai L, Hu W, Zhang J, Wu D, et al. Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China. Front Oncol. 2025; 15: 1577607.

[14] Shih JY, Luo YH, Chang GC, Chang JW, Wang CC, Yang TY, et al. Real-world evidence of lorlatinib therapy in patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. J Formos Med Assoc. 2024; 123: 875-81.

[15] Biswas B, Ghadyalpatil NS, Patil S, Patel A, Ganguly S, Rathore A, et al. Real world study of safety and efficacy of lorlatinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India - a multicentre chart review study (ROSELAND) . Ecancermedicalscience. 2024; 18: 1667.

[16] Goto Y, Kenmotsu H, Tamiya M, Murakami S, Kurata T, Yanagitani N, et al. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan. JTO Clin Res Rep. 2023; 4: 100508.

[17] Alexander M, Wei J, Parakh S, John T, Kao S, Nagrial A, et al. LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC. JTO Clin Res Rep. 2023; 4: 100490.

[18] Baldacci S, Besse B, Avrillon V, Mennecier B, Mazieres J, Dubray-Longeras P, et al. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. Eur J Cancer. 2022; 166: 51-9.

[19] Hochmair MJ, Fabikan H, Illini O, Weinlinger C, Setinek U, Krenbek D, et al. Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis. Pharmaceuticals (Basel). 2020; 13: 371.

[20] Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, et al. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Ther Adv Med Oncol. 2021; 13: 1758835920980558.

[21] Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, et al. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. J Thorac Oncol. 2020; 15: 1484-96.

[22] Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, et al. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer. 2020; 148: 48-54.

[23] Imyanitov EN, Preobrazhenskaya EV, Orlov SV. Current status of molecular diagnostics for lung cancer. Explor Target Antitumor Ther. 2024; 5: 742-65.

[24] Aleksakhina SN, Kashyap A, Imyanitov EN. Mechanisms of acquired tumor drug resistance. Biochim Biophys Acta Rev Cancer. 2019; 1872: 188310.

[25] Xie J, Gao Y, Xu W, Zhu J. Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer. Int J Gen Med. 2025; 18: 2151-71.

[26] Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016; 7: 13665.

[27] García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, et al. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol. 2019; 9: 849.

[28] Poei D, Ali S, Ye S, Hsu R. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. Cancer Drug Resist. 2024; 7: 20.

[29] Pan Y, Deng C, Qiu Z, Cao C, Wu F. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol. 2021; 11: 713530.

[30] Li H, Wang C, Guo C. Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system. Front Pharmacol. 2024; 15: 1385036.